Company
ACRO BIOMEDICAL CO., LTD.
ACRO Biomedical was founded in June 2014 in Kaohsiung, Taiwan, by Dr. Dar-Jen Hsieh and a group of scientists and physicians. ACRO Biomedical develops and produces biomaterial medical devices for human tissue engineering and regenerative medicine (TERM). ACRO Biomedical uses its proprietary supercritical CO₂ extraction technology to remove cells, fat and non-collagenous proteins from animal tissues, while keeping the undiminished collagen scaffold as the biomaterial for high-end medical devices in the medical regenerative field of wound care, orthopedics, dentistry, ophthalmology, aesthetic microsurgery, cardiovascular and neural surgery, etc.
ACRO BIOMEDICAL CO., LTD. is a publicly traded company. It trades under the ticker ACBM.
Leadership
Former
Recent developments
AI summary of recent coverageRecent coverage of ACRO BIOMEDICAL has focused on significant leadership changes, with the company announcing new appointments for Chairman, CEO, and CFO effective September 2, 2026. The coverage also highlights the company's regulatory expansion in India through CDSCO approval, alongside reports of going concern risks related to cash constraints and lack of revenue generation.
Summarized from the headlines in the sidebar; see each source for the full story.